FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3128481523> ?p ?o ?g. }

• W3128481523 endingPage "565" @default.
• W3128481523 startingPage "565" @default.
• W3128481523 abstract "The extent of changes in estradiol levels in male patients with hormone receptor-positive breast cancer receiving standard endocrine therapies is unknown. The sexual function and quality of life related to those changes have not been adequately evaluated.To assess the changes in estradiol levels in male patients with breast cancer after 3 months of therapy.This multicenter, phase 2 randomized clinical trial assessed 56 male patients with hormone receptor-positive breast cancer. Patients were recruited from 24 breast units across Germany between October 2012 and May 2017. The last patient completed 6 months of treatment in December 2017. The analysis data set was locked on August 24, 2018, and analysis was completed on December 19, 2018.Patients were randomized to 1 of 3 arms: tamoxifen alone or tamoxifen plus gonadotropin-releasing hormone analogue (GnRHa) or aromatase inhibitor (AI) plus GnRHa for 6 months.The primary end point was the change in estradiol levels from baseline to 3 months. Secondary end points were changes of estradiol levels after 6 months, changes of additional hormonal parameters, adverse effects, sexual function, and quality of life after 3 and 6 months.In this phase 2 randomized clinical trial, a total of 52 of 56 male patients with a median (range) age of 61.5 (37-83) years started treatment. A total of 3 patients discontinued study treatment prematurely, 1 in each arm. A total of 50 patients were evaluable for the primary end point. After 3 months the patients' median estradiol levels increased by 67% (a change of +17.0 ng/L) with tamoxifen, decreased by 85% (-23.0 ng/L) with tamoxifen plus GnRHa, and decreased by 72% (-18.5 ng/L) with AI plus GnRHa (P < .001). After 6 months, median estradiol levels increased by 41% (a change of +12 ng/L) with tamoxifen, decreased by 61% (-19.5 ng/L) with tamoxifen plus GnRHa, and decreased by 64% (-17.0 ng/L) with AI plus GnRHa (P < .001). Sexual function and quality of life decreased when GnRHa was added but were unchanged with tamoxifen alone.This phase 2 randomized clinical trial found that AI or tamoxifen plus GnRHa vs tamoxifen alone led to a sustained decrease of estradiol levels. The decreased hormonal parameters were associated with impaired sexual function and quality of life.ClinicalTrials.gov Identifier: NCT01638247." @default.
• W3128481523 created "2021-02-15" @default.
• W3128481523 creator A5002739406 @default.
• W3128481523 creator A5003405177 @default.
• W3128481523 creator A5007561826 @default.
• W3128481523 creator A5011232197 @default.
• W3128481523 creator A5011672118 @default.
• W3128481523 creator A5011764682 @default.
• W3128481523 creator A5017517167 @default.
• W3128481523 creator A5027186034 @default.
• W3128481523 creator A5030223933 @default.
• W3128481523 creator A5031213698 @default.
• W3128481523 creator A5045891981 @default.
• W3128481523 creator A5050978422 @default.
• W3128481523 creator A5055059973 @default.
• W3128481523 creator A5057181684 @default.
• W3128481523 creator A5059885667 @default.
• W3128481523 creator A5068818204 @default.
• W3128481523 creator A5075265190 @default.
• W3128481523 creator A5077307794 @default.
• W3128481523 creator A5078993145 @default.
• W3128481523 creator A5087559224 @default.
• W3128481523 creator A5091848376 @default.
• W3128481523 date "2021-04-01" @default.
• W3128481523 modified "2023-10-17" @default.
• W3128481523 title "Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men" @default.
• W3128481523 cites W118218729 @default.
• W3128481523 cites W1814360603 @default.
• W3128481523 cites W2024672113 @default.
• W3128481523 cites W2040720403 @default.
• W3128481523 cites W2050939765 @default.
• W3128481523 cites W2066920175 @default.
• W3128481523 cites W2086240335 @default.
• W3128481523 cites W2088795431 @default.
• W3128481523 cites W2090516581 @default.
• W3128481523 cites W2132662021 @default.
• W3128481523 cites W2133831815 @default.
• W3128481523 cites W2141925819 @default.
• W3128481523 cites W2141926802 @default.
• W3128481523 cites W2153879164 @default.
• W3128481523 cites W2163351051 @default.
• W3128481523 cites W2165751593 @default.
• W3128481523 cites W2167027232 @default.
• W3128481523 cites W2168268595 @default.
• W3128481523 cites W2169649287 @default.
• W3128481523 cites W2189916683 @default.
• W3128481523 cites W2214665719 @default.
• W3128481523 cites W2232585277 @default.
• W3128481523 cites W2314200711 @default.
• W3128481523 cites W2333641069 @default.
• W3128481523 cites W2609928112 @default.
• W3128481523 cites W2726659407 @default.
• W3128481523 cites W2765994983 @default.
• W3128481523 cites W2766828098 @default.
• W3128481523 cites W2781525129 @default.
• W3128481523 cites W2803278751 @default.
• W3128481523 cites W2806866264 @default.
• W3128481523 cites W2808444757 @default.
• W3128481523 cites W2811313942 @default.
• W3128481523 cites W3006424097 @default.
• W3128481523 cites W3010197652 @default.
• W3128481523 cites W4243051815 @default.
• W3128481523 cites W4245259160 @default.
• W3128481523 cites W4246847424 @default.
• W3128481523 cites W4248422588 @default.
• W3128481523 cites W4252714226 @default.
• W3128481523 cites W4254749365 @default.
• W3128481523 doi "https://doi.org/10.1001/jamaoncol.2020.7442" @default.
• W3128481523 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7863014" @default.
• W3128481523 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33538790" @default.
• W3128481523 hasPublicationYear "2021" @default.
• W3128481523 type Work @default.
• W3128481523 sameAs 3128481523 @default.
• W3128481523 citedByCount "20" @default.
• W3128481523 countsByYear W31284815232021 @default.
• W3128481523 countsByYear W31284815232022 @default.
• W3128481523 countsByYear W31284815232023 @default.
• W3128481523 crossrefType "journal-article" @default.
• W3128481523 hasAuthorship W3128481523A5002739406 @default.
• W3128481523 hasAuthorship W3128481523A5003405177 @default.
• W3128481523 hasAuthorship W3128481523A5007561826 @default.
• W3128481523 hasAuthorship W3128481523A5011232197 @default.
• W3128481523 hasAuthorship W3128481523A5011672118 @default.
• W3128481523 hasAuthorship W3128481523A5011764682 @default.
• W3128481523 hasAuthorship W3128481523A5017517167 @default.
• W3128481523 hasAuthorship W3128481523A5027186034 @default.
• W3128481523 hasAuthorship W3128481523A5030223933 @default.
• W3128481523 hasAuthorship W3128481523A5031213698 @default.
• W3128481523 hasAuthorship W3128481523A5045891981 @default.
• W3128481523 hasAuthorship W3128481523A5050978422 @default.
• W3128481523 hasAuthorship W3128481523A5055059973 @default.
• W3128481523 hasAuthorship W3128481523A5057181684 @default.
• W3128481523 hasAuthorship W3128481523A5059885667 @default.
• W3128481523 hasAuthorship W3128481523A5068818204 @default.
• W3128481523 hasAuthorship W3128481523A5075265190 @default.
• W3128481523 hasAuthorship W3128481523A5077307794 @default.
• W3128481523 hasAuthorship W3128481523A5078993145 @default.
• W3128481523 hasAuthorship W3128481523A5087559224 @default.

• next